Hansoh Pharmaceutical Group Company Limited (HK:3692) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Hansoh Pharmaceutical Group Company Limited has entered into an exclusive licensing agreement with Guangzhou Lupeng Pharmaceutical Co., Ltd. to develop and commercialize the drug LP-168 in China. The agreement includes milestones and royalty payments that could total up to RMB729 million. LP-168, currently in Phase II clinical trials, is a promising treatment for non-tumor indications and is part of Hansoh’s strategic growth in the pharmaceutical industry.
For further insights into HK:3692 stock, check out TipRanks’ Stock Analysis page.